Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study

被引：0
|
作者：
Orlandi, Armando
Pinto, Carmine
Calegari, Maria Alessandra
Normanno, Nicola
Maiello, Evaristo
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, M. Giulia
Bergamo, Francesca
Tonini, Giuseppe
Tamberi, Stefano
Avallone, Antonio
Latiano, Tiziana Pia
Rosati, Gerardo
Pazzola, Antonio
Ballestrero, Alberto
Zaniboni, Alberto
Formica, Vincenzo
Barone, Carlo
机构：
[1] Fdn Policlini Univ A Gemelli IRCCS, UOC Oncol Med, Rome, Italy
[2] Azienda USL IRCCS Reggio Emilia, Med Oncol Unit, Reggio Emilia, Italy
[3] Fdn Policlin Univ Agostino Gemelli, Med Oncol Unit, IRCCS, Rome, Italy
[4] G Pascale Foudat, Natl Canc Inst Naples, Brusciano, Italy
[5] Fdn IRCSS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[6] Careggi Univ Hosp, Clin Oncol Unit, Dept Expt & Clin Med, Florence, Italy
[7] Azienda Osped ARNAS Garibaldi, Med Oncol, Catania, CT, Italy
[8] Ist Europeo Oncol, Milan, Italy
[9] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Med Oncol 1, Padua, Italy
[10] Univ Campus Biomed, Dept Med Oncol, Rome, Italy
[11] Oncol Unit, Osped Santa Maria Croci, Ravenna, Italy
[12] Fondazione G Pascale Napoli, Ist Nazl Tumori, Naples, Italy
[13] Fdn IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[14] Azienda Osped S Carlo, Potenza, Italy
[15] Osped Civili SS Annunziata, Dept Med Oncol, Sassari, Italy
[16] Univ Genoa, Genoa, Italy
[17] CdC Poliambulanza, Brescia, Italy
[18] Univ Rome, Med Oncol Unit, Tor Vergata Clin Ctr, Rome, RM, Italy
[19] Fdn Policlin Univ A Gemelli IRCCS Roma, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3603
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study
    Yamazaki, K.
    Yasui, H.
    Yamaguchi, K.
    Kagawa, Y.
    Kuboki, Y.
    Yoshino, T.
    Gamoh, M.
    Komatsu, Y.
    Satake, H.
    Goto, M.
    Tanioka, H.
    Oki, E.
    Kotaka, M.
    Makiyama, A.
    Denda, T.
    Soeda, J.
    Shibya, K.
    Iwata, M.
    Oba, K.
    Kato, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - an interim analysis of the CEBIFOX trial
    Hoehler, T.
    Decker, T.
    Schimanski, C.
    Schmitz, S.
    Kanzler, S.
    Rauh, J.
    Vehling-Kaiser, U.
    Bernhard, H.
    Hoffmann, T.
    Niederle, N.
    von Verschuer, U.
    von Wichert, G.
    Wagner, T.
    Klein, M.
    ONKOLOGIE, 2013, 36 : 105 - 105
  • [43] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
    Kim, Tae Won
    Elme, Anneli
    Park, Joon Ho
    Udrea, Anghel Adrian
    Manojlovic, Nebojsa S.
    Guan, Xuesong
    Jung, A. Scott
    Vrdoljak, Eduard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade
    Randon, Giovanni
    Nakamura, Yoshiaki
    Yaeger, Rona
    Lonardi, Sara
    Cremolini, Chiara
    Elez, Elena
    Nichetti, Federico
    Ghelardi, Filippo
    Nasca, Vincenzo
    Bergamo, Francesca
    Conca, Veronica
    Montana, Javier Ros
    Maddalena, Giulia
    Prisciandaro, Michele
    Bando, Hideaki
    Schrock, Alexa Betzig
    Walch, Henry S.
    Yoshino, Takayuki
    Pietrantonio, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).
    Tabernero, Josep
    Van Cutsem, Eric
    Prausova, Jana
    Isambert, Nicolas
    Neuzillet, Cindy
    Siena, Salvatore
    Pietrantonio, Filippo
    Falk, Stephen
    Wainberg, Zev A.
    Raghav, Kanwal Pratap Singh
    Campbell, Nicole
    Liu, Eva
    Esser, Regina
    Salim, Shaista
    Beier, Frank
    Adrian, Svenja
    Elez, Elena
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Impact of early tumour shrinkage (ETS) on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line treatment in three randomised panitumumab trials: An exploratory study-level meta-analysis
    Karthaus, M.
    Rivera, F.
    Valladares-Ayerbes, M.
    Gallego, J.
    Koukakis, R.
    Demonty, G.
    Douillard, J. -Y
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 93 - 94
  • [49] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [50] Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
    Ciardiello, F.
    Martinelli, E.
    Cardone, C.
    Troiani, T.
    Normanno, N.
    Pisconti, S.
    Bordonaro, R.
    Nappi, A.
    Giuliani, F.
    Biglietto, M.
    Barone, C.
    Rachiglio, A. M.
    Montesarchio, V.
    Cinieri, S.
    Rizzi, D.
    Febbraro, A.
    Latiano, T.
    Modoni, G.
    Colucci, G.
    Maiello, E.
    ANNALS OF ONCOLOGY, 2017, 28 : 9 - 9
12345